News Update

COVID-19: Global death tally inches close to 7.5 lakh including 48K in IndiaCBDT reconstitutes NeAC under Faceless SchemeTax Charter Launch - Taxpayer now assured of courteous behavior: PMCBDT directs Investigation & Central Charges not to send any Communication to assessees till further orderCBDT diverts 26 posts of CCIT + 129 posts of PCIT & 3 posts of CIT to National e-Assessment Centre AND re-designates posts diverted earlierCBIC reduces tariff value of gold and gold barsCBDT issues orders u/s 119 - International Tax & Central Charges assessment orders brought under Faceless Scheme + DG(Inv) to authorise all Surveys u/s 133APM says Govt trying for seamless, painless & faceless tax systemPM launches Income Tax ‘Transparent Taxation - Honouring the Honest’ Platform containing Taxpayers’ Charter & Faceless Assessment detailsChina retaliates; imposes anti-dumping duty on Indian fibre optic goodsIndia-China Faceoff - Do not keep quiet & take it on Chin! New Delhi needs to counter Beijing's Chequebook Diplomacy!CX - It cannot be said that notification 65/95-CE is unconditional and absolute - sub-section (1A) of Section 5A is not attracted - no irregularity in availment of CENVAT credit and payment of duty: CESTATCOVID-19 - Expert Group on Vaccine deliberates on delivery mechanismST - Intelsat, being a relay station itself, cannot be said to be a 'broadcaster'- charges paid by appellant to Intelsat not taxable under reverse charge: CESTATGovt allows registration of Electric Vehicles without batteriesCus - If issue is to be adjudicated by just reiterating the findings and decisions recorded in previous o-in-o which has been set aside by tribunal, then the AA has failed in task assigned to him for reconsideration of matter: CESTATCOVID-19 - Global tally surpasses 20.5 million, says Johns Hopkins UnivFormer President Pranab Mukherjee continues to be ventilator supportJammu to Delhi travel time will come to just about six hours: MoSMoney Laundering - Huge transactions in HK and US Dollars unearthedGST Data safe with GSTN - don't worry, there's a solution
 
COVID-19 - Govt gives nod for Emergency Use to Itolizumab

By TIOL News Service

NEW DELHI, JULY 11, 2020: Itolizumab (rDNA origin), a monoclonal antibody which was already approved for severe chronic plaque psoriasis, has now been granted Restricted Emergency Use authorisation by the Drugs Controller General of India (DCGI) based on clinical trials data.

M/s Biocon has been manufacturing and marketing this drug for the treatment of patients with moderate to severe chronic plaque psoriasis since 2013 under brand name Alzumab. This indigenous drug has now been repurposed for COVID-19.

M/s Biocon has presented the Phase II clinical trial results generated in COVID-19 patients to DCGI. The results of these trials were deliberated in the Subject Expert Committee of DCGI's office.

Details of primary endpoint of mortality, other key endpoints of lung function such as improvement in PaO2 and O2 saturation were presented. Key inflammatory markers IL-6, TNFa etc., were presented to have reduced significantly with the drug thereby preventing hyper- inflammation in COVID-19 patients.

After detailed deliberation and taking into account the recommendations of the Committee, DCGI has decided to grant permission to market the drug under Restricted Emergency Use of the drug for the treatment of Cytokine Release Syndrome  (CRS) in moderate to severe Acute Respiratory Distress Syndrome (ARDS) patients due to COVID-19, subject to some conditions like informed consent of patients, a risk management plan, to be used in hospital set up only etc.

The average cost of treatment with this indigenous drug i.e Itolizumab is also lesser than comparable drugs which are part of the “Investigational Therapies” indicated in the Clinical Management Protocol for COVID-19 of the Ministry of Health and Family Welfare.


POST YOUR COMMENTS